periodontal disease and systemic health in women · periodontal disease and systemic health in...

Post on 09-Apr-2018

219 Views

Category:

Documents

2 Downloads

Preview:

Click to see full reader

TRANSCRIPT

Periodontal Disease and Systemic Health in Women

Marjorie Jeffcoat DMDMorton Amsterdam DeanUniversity of Pennsylvania SDM

Bullemia

Patients fear being overweight

Lost control over eating

Eat and purge

Tend to be normal weight

May have electrolyte imbalances leading to arrythmias etc.

Bullemia – Dental Findings

Enamel erosionTooth sensitivitySmall, purplish-red lesions on the palate due to contact with objects used to induce vomitingTeeth may be discolored or look dull from the acidXerostomia, dry lips and skin around the mouthSwollen lymph nodes and salivary glands in severe casesPatients often deny the diseaseDental finding may aid in ascertainment of cases

Pregnancy

Pregnancy gingivitis

Hormones plus plaque bacteria increase the gingival inflammationPrevention

Home care and scaling and root planningTreatment Scaling and root planing

Antimicrobial rinses where indicatedTetracyclines are not indicated in pregnant patients

Osteoporosis

Loss of bone densityPropensity to fracture

Especially,HipsWristSpine

May result in widows hump

Risk factors for Osteoporosis

Low peak bone mineral densityLow body mass indexDiet: insufficient calcium 1000-1500mg/dayWomenPostmenopausalLack of EstrogenSmoking

Risk factors for Osteoporosis

DrugsCorticosteroids

Possible to lose 10% of bone mineral in one yearsCytotoxic DrugsEstrogen antagonists

Lack of exercise Propensity to fall

Progression of alveolar bone loss and osteoporosis

Sites with osteoporosis and periodontitis have the highest rate of bone loss

periodontallyhealthy periodontal

disease

no osetoporosis

osteoporosis

0

0.2

0.4

0.6

0.8

1

1.2m

m b

one

loss

/yr

3-year Alveolar Bone Loss (mm)

c

What to do?

Prevention, prevention, preventionInclude questions on osteoporosis in the medical historyEducate about diet, exercise, etc.Refer for treatment

Prevent and treat periodontal disease

Prevention of osteoporosis

EducationAttain sufficient peak bone mass

Calcium and milkAvoid sodaAvoid smoking

Attain sufficient bone massExerciseAppropriate drug treatment

Pharmacologic approaches

EstrogensNasal calcitoninBisphosphonates

E.g. alendronate, risendronateDesigner estrogensPTH (daily injections)

Bisphosphonates-Risks

Patients must drink a full glass of waterRisk of esophageal irritation

Intravenous Bisphosphonates-Risks in patients with bone cancer

Patients usually are also taking cytotoxic drugs to treat the bone cancerCases of osteonecrosis of the jaw have been reported

Effect of bisphosphonates on alveolar bone

Jeffcoat et al 2006Double blind randomized controlled clinical trials70 mg alendronate weekly320 SubjectsAssess safety and efficacy

Dental Implants

EndosseousOsseointegratedUsually titanium, titanium alloy, with or without a bioactive coating

Risk factors for dental implants

Smoking.Factors that effect healing of bone (e.g. steroids, diabetes etc.)Untreated periodontal diseaseAnatomy (inadequate bone to place implants (grafting may be needed).Poor bone quality Inadequate practitioner training and/or experiencePatient compliance

Risk Factors For ONJ and Failure

SmokingDiabetesPre-existing infectionCortico-steroidsDrugs that inhibit the immune responseUntreated periodontal diseaseAllergy

ONJ due to metal allergy

Failing Implant - Infection

Bone graft + membrane

Pretreatment one month five years

ONJ - Radiographic

ONJ - Clinical

Do oral bisphosphonates cause implant failure – after 8 years

32 consecutive patients taking bisphosphonates for osteoporosis, and 32 controlsTracked for at least 5 years after implants placed, received bisphosphonates for 3 yrs before placementLooked for evidence of

implant lossloss of >2mm bonemobilityONJ

000010

00009

00008

00007

00006

00005

00004

00003

00002

00001

ONJMobilityBone lossImp lossPt No.

Oral bisphosphonates

Low doseAll bisphosphonates are not alikeControlled studies involve tens of thousands of subjectsPost market studies involve millionsCannot calculate a risk of ONJ – it is very small or non existent

Intravenous bisphosphonates

High doseAll bisphosphonates are not alikeStandard of care along with high doses of steroids and cytotoxic drugs (both cause bone problems) to treat cancers such as multiple myelomaDifficult to calculate risk of ONJIn Penns experience it is 1-3% but it is unknown if the cancer, the cytotoxic drugs, steroids, or high dose bisphosphonates caused the problem

Stay tuned

More studies are on the way!

top related